What happened, in summary

Mark Scragg knew cancer risk ran in his family after he and several relatives learned they had Lynch syndrome. In May 2021, persistent fatigue and stomach pain led him to move up his yearly endoscopy and colonoscopy. Doctors found a stomach tumor, and additional scans showed cancer involving lymph nodes. His cancer was described as Stage IV, and surgery was not considered an option. Mark was 33.

After seeking a second opinion at Dana-Farber during COVID-19 travel restrictions, Mark returned to Canada for chemotherapy combined with immunotherapy. The treatment produced a strong early response: after about 3 months, scans showed no sign of the stomach tumor. His Canadian oncology team and Dana-Farber’s Lynch Syndrome Center continued coordinating his care and hereditary-cancer surveillance.

By the article’s 2025 update, Mark had completed active cancer treatment, was feeling well, and his cancer was described as remaining largely in remission. He continued regular screening because Lynch syndrome increases the risk of several cancers. Family support remained central throughout his treatment, and Mark and his wife were preparing to welcome their third child in January 2025.